
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
VIENNA - The ascomycin derivative pimecrolimus (ASM 981, Elidel) - currently in Phase III trials for the treatment of atopic dermatitis (topical) and psoriasis (oral) - exhibits skin-specific anti-inflammatory activity and has low potential for immunosuppression in both its topical and oral formulations.






